Document is current
Any future updates will be listed below
-
Authors
Ogier du Terrail, Jean https://orcid.org/0000-0001-6320-819X
Klopfenstein, Quentin
Li, Honghao
Mayer, Imke
Loiseau, Nicolas
Hallal, Mohammad https://orcid.org/0000-0003-1624-9647
Debouver, Michael
Camalon, Thibault
Fouqueray, Thibault
Arellano Castro, Jorge
Yanes, Zahia
Dahan, Laëtitia
Taïeb, Julien https://orcid.org/0000-0002-9955-4753
Laurent-Puig, Pierre https://orcid.org/0000-0001-8475-5459
Bachet, Jean-Baptiste https://orcid.org/0000-0003-4337-286X
Zhao, Shulin https://orcid.org/0000-0001-8233-0115
Nicolle, Remy https://orcid.org/0000-0001-8084-1173
Cros, Jérôme https://orcid.org/0000-0002-4935-3865
Gonzalez, Daniel https://orcid.org/0000-0002-6530-2355
Carreras-Torres, Robert https://orcid.org/0000-0002-2925-734X
Garcia Velasco, Adelaida https://orcid.org/0000-0001-8388-0522
Abdilleh, Kawther
Doss, Sudheer
Balazard, Félix https://orcid.org/0000-0003-3336-0128
Andreux, Mathieu
-
Funding
Funding for this research was provided by:
Owkin, Inc.
- License Information
-
More Information
Article History
Received: 28 October 2024
Accepted: 24 July 2025
First Online: 13 August 2025
Competing interests
: The authors declare the existence of a financial competing interest. Some authors are or were employed by Owkin, Inc. during their time on the project (J. O.d.T, Q.K., M.A., H.L, I.M., N.L., M.H., M.D., T.C., T.F., F.B., J.A.C., Z.Y.). P. L.-P. has received honoraria for consulting and/or advisory board for AMGEN, Pierre Fabre, Biocartis, Servier and BMS. J.B. Bachet has received personal fees from Amgen, Bayer, Bristol Myers Squibb, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Pierre Fabre, Sanofi, Servier, and non-financial support from Amgen, Merck Serono, and Roche, outside the submitted work. J. T. has received honoraria as a speaker and/or in an advisory role from AMGEN, Astelllas, Astra Zeneca, Boehringer, BMS, Merck KGaA, MSD, Novartis, ONO pharmaceuticals, Pierre Fabre, Roche Genentech, Sanofi, Servier and Takeda. A. G. V. has received honoraria as a speaker and/or in an advisory role from Astra Zeneca, Merck Serono, MSD, Novartis, Roche Genentech, Sanofi, and Servier. R. N. has received honoraria as a consultant from Cure51. Part of this work corresponding to work-package 4 of the RHU AI-TRIOMPH and carried out by Owkin France was supported by Agence Nationale de la Recherche as part of the France 2030 plan with reference ANR-23-RHUS-0012 (H.L and F.B.). The remaining authors declare no competing interests.
